The regenerative medicine field remains united conceptually in that the players are all motivated to use cells, engineered cells, cells combined with devices, and cell derivatives for treating disorders. However, the field is diverse encompassing everything from cell-derived products that are not regulated, to somatic cell products and products derived from stem cells. These products are being used in innovative ways that, in some cases, represent incremental change from existing activity or a small extension of expertise; examples of this are seen in the blood banking and marrow transplant industries. While other changes are completely novel uses of new types of cells including neural stem cells, mesenchymal stem cells, and, more recently, induced pluripotent stem cells. Perhaps the most radical change has been the newest results on somatic cell nuclear transfer, which offer an opportunity to treat mitochondrial diseases, and the development of technology to make three–D biological and engineered composites.
Attendees will learn:
A brief history of stem-cell advancements.
The safety issues with stem-cell therapy and how clinical trials are designed.
The useful therapies expected to flow from stem-cell technology.